entertainment -WSS

entertainment

author：Wikipedia 2025-09-14 21:59:32 - browse：19

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Stroke deaths set to near 10 million globally by 2050

WSS

Prior authorization reform is both possible and imperative

Future doctors need a strong humanities education

Cardiologists urge adding sexual orientation, gender identity to health records

Why age limits for politicians are a terrible idea

High breast density mammograms need follow

CVS is on a mission to consolidate health care. Will it work?

hotspot

entertainment

knowledge

Medical leaders decry Supreme Court decision on affirmative action

3 questions for the future of Biden's cancer moonshot

Medicare proposal to cover medical devices draws a mixed reaction

Head of FDA's diagnostics center, who led through Covid, retires

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA panel signals lack of confidence in Amgen cancer drug data

Dobbs anniversary: the lost opportunity of abortion as health care

FDA endorses new sterilization method for medical devices

Supreme Court strikes down use of affirmative action

A Q&A with the global head of Boehringer Ingelheim's innovation unit

hotspot

Why age limits for politicians are a terrible idea

Immunocompromised patients offer clues on chronic Covid

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Maisha Meds is a PBM, but don't call it that

Flu vaccine reformulation won't be easy, manufacturers warn

What to expect at HLTH 2023, the health care industry conference

focus

explore

explore

hotspot